Summary: Researchers have secured funding to develop a pioneering multi-organ “organ-on-chip” device. Named the GlucoBrain project, this three-year pilot study will physically connect living human cellular models of the gut, pancreas, and brain within a miniature biochip.
By tracking real-time molecular signaling and cellular responses to varying glucose and hormone levels, the project aims to uncover the mysterious biological mechanisms behind why diabetes significantly increases the risk of cognitive decline, learning difficulties, and Alzheimer’s disease.
Key Facts
- The Connected Biochip: GlucoBrain is a first-of-its-kind multi-organ system that replicates the complex, three-dimensional cellular connections and communication networks between the brain, gut, and pancreas.
- Bypassing the Petri Dish: Moving beyond static, traditional flat cell cultures, organ-on-chip technology grows living human cells in specialized 3D structures with controlled nutrient flows, allowing cells to interact, mature, and respond more naturally.
- Decoupling the Diabetes-Dementia Link: While diabetes is clinically linked to cognitive impairment and memory loss, current research models fail to isolate how metabolic changes in the gut and pancreas directly sabotage brain function. GlucoBrain allows researchers to isolate individual cell types to map this cellular communication in real time.
- Phased System Construction: Beginning in October, the interdisciplinary team will first engineer independent chip modules for the gut, pancreas, and brain before structurally integrating them into a unified, fluidically linked multi-organ circuit.
- The Medical Future: By validating drug behaviors on human cells, this platform aims to drastically accelerate drug discovery, phase out reliance on animal testing models, and lay the foundation for personalized medicine using a patient’s own extracted cells.
Source: University of Bath
A University of Bath-led project has secured £500,000 to develop a first-of-its-kind ‘organ-on-chip’ device that replicates connections between the brain, gut and pancreas.
The GlucoBrain project will allow researchers to track how signals move between the organs and uncover why diabetes may lead to changes in memory and cognition.
The study is led by world-leading experts in Lab-on-Chip technology at Bath, with collaboration from the University of Oxford and Johns Hopkins University. Their findings could pave the way for new treatments to improve the lives of millions of people affected by diabetes, dementia, or both.
Diabetes and Alzheimer’s disease are two of the world’s most pressing health problems, especially in ageing societies. While diabetes is widely known to affect the heart, kidneys and eyes, growing evidence suggests it is also linked with problems in memory, learning and brain function. However, the biological mechanisms behind this link remain poorly understood.
Dr Despina Moschou, the project’s lead, said: “Our gut, pancreas and brain are constantly communicating via a network of signals, helping us regulate hunger and blood sugar. But we still don’t fully understand how these signals interact at a cellular level and why glucose levels are linked to cognitive decline.
“By creating a connected system on a chip, we can study in real time how signals travel between organs, how diabetes may impair brain function, and how new drugs could help.”
Building a multi-organ model
Most current knowledge on the link between diabetes and dementia comes from animal studies, simple cell cultures and patient studies. While these are useful, they don’t fully and accurately capture all the complex interactions between our organs, hormones and cells.
Organ-on-chip technology uses living human cells in miniature devices that mimic how organs work in the body. Unlike cell cultures grown in a petri dish, these devices allow cells to grow in three dimensions, receive a controlled supply of nutrients and interact more naturally. For the first time, researchers will also be able to isolate these individual organs and cell types to understand exactly how they communicate at a molecular level.
The three-year project starts in October, bringing together engineers, clinicians, biologists and computer scientists to model the complex disease interactions. The team will first develop individual chip models for the gut, pancreas and brain, before connecting them into a multi-organ system. They will gradually increase complexity and measure how each organ responds to glucose, hormones and different drug treatments.
Researchers from the University of Oxford will provide core clinical expertise in diabetes and metabolic disease, ensuring models are physiologically accurate. The team from Johns Hopkins University brings specialist expertise in Alzheimer’s disease and brain organoids.
Unlocking future potential
GlucoBrain is a pilot project that will help researchers understand exactly how diseases like diabetes and dementia work at a deeper, biological level. This early-stage research will build the foundations for even more advanced and realistic models, bringing together more organs and cell types. By harnessing the power of artificial intelligence, the devices have the potential to reveal new insights into how diseases emerge and develop.
Dr Moschou continued: “Not only would these devices give us an unprecedented way to study diseases, but they could help speed up drug discovery and testing, reducing reliance on animal models and making results more relevant to humans. In the long term, they could pave the way for personalised medicine, using a patient’s own cells to identify the most effective treatment.”
The project is funded by the Engineering and Physical Sciences Research Council (EPSRC) Health Technologies Connectivity Awards.
Key Questions Answered:
A: Under normal conditions, your gut, pancreas, and brain exist in a state of constant chemical conversation, exchanging hormonal signals to regulate hunger, insulin, and blood sugar. When diabetes disrupts this loop, the metabolic chaos ripples outward. Growing clinical evidence shows that chronic glucose imbalances directly impair memory and learning centers, but until now, we lacked a way to watch how these destructive signals travel from your digestive organs into your brain tissue.
A: Animals are invaluable for broad system tracking, but their basic cellular biology, hormone receptors, and brain wiring differ fundamentally from ours. Furthermore, in a living animal or human patient, changing one metabolic factor instantly changes exercise, mood, and daily routines, turning the data into a messy puzzle. An organ-on-chip device isolates living, three-dimensional human cells in an environment that behaves exactly like the human body, providing pristine, highly relevant data without interspecies translation errors.
A: The long-term goal of the GlucoBrain platform is to establish a direct pathway to personalized medicine. In the future, doctors could harvest a small sample of your own stem cells, grow your personal gut-pancreas-brain network on a custom biochip, and expose it to dozens of different diabetes or dementia medications. By watching your actual cells react in real time on the chip, clinicians can pinpoint the exact drug cocktail that works best for your specific biology before you ever swallow a single pill.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neurotech and dementia research news
Author: Sarah Baker-Gaunt
Source: University of Bath
Contact: Sarah Baker-Gaunt – University of Bath
Image: The image is credited to Neuroscience News
